Evidence map›Paper›PMID 27066377›Full record

ArticleSpringerPlus2016

Clinical significance of serum CA125 in diffuse malignant mesothelioma.

Xu Cheng, Hong-Feng Gou, Ji-Yan Liu, De-Yun Luo, Meng Qiu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SpringerPlus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xu ChengDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Xiang Street, Chengdu, 610041 Sichuan Province China ; West China School of Medicine, Sichuan University, Chengdu, Sichuan China.
Hong-Feng GouDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Xiang Street, Chengdu, 610041 Sichuan Province China.
Ji-Yan LiuDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Xiang Street, Chengdu, 610041 Sichuan Province China.
De-Yun LuoDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Xiang Street, Chengdu, 610041 Sichuan Province China.
Meng QiuDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Xiang Street, Chengdu, 610041 Sichuan Province China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant mesothelioma (MM) is a rare and fatal neoplasm. For diffuse malignant mesothelioma (DMM) patients that were not suitable for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, systemic chemotherapy is the main treatment. There are no convenient tumor markers to predict the efficacy of treatment and disease progression. This study aimed to evaluate serum CA125 level as a biochemical marker of response to therapy and prognosis in patients with DMM.

methodsA retrospective study was performed in a single medical institution from April 2008 to April 2014. Overall survival (OS) and prognostic factors were assessed.

resultsForty-one patients were included with a median age of 53 years. The median OS of all patients was 10 months. Patients with baseline CA125 > 280 U/ml had worse OS compared with the patients that baseline CA125 ≤ 280 U/ml. Baseline level of CA125, stage of disease, primary tumor location and systemic chemotherapy were independent prognostic factors associated with OS. In patients who received systemic chemotherapy, the decline in serum CA125 was associated with favorable OS and objective response according to modified Response Evaluation Criteria in Solid Tumors criteria.

conclusionsThe baseline level of serum CA125, accompanied with stage of disease, primary tumor location and systemic chemotherapy, could be regarded as independent prognostic factors for DMM patients. Otherwise, the change in serum CA125 can predict OS and response to systemic chemotherapy.

Indexed as

CA-125 antigenDrug therapyMesotheliomaPrognosis

Identifiers

PMID27066377
PMCPMC4805673
OpenAlexW2308048091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.